scholarly journals Malignant pleural mesothelioma: adjuvant therapy with radiation therapy

2017 ◽  
Vol 5 (11) ◽  
pp. 242-242 ◽  
Author(s):  
Kenneth E. Rosenzweig
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Therapy ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up

Lung Cancer ◽  
2014 ◽  
Vol 83 (1) ◽  
pp. 78-82 ◽  
Author(s):  
Emilio Minatel ◽  
Marco Trovo ◽  
Jerry Polesel ◽  
Tania Baresic ◽  
Alessandra Bearz ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Malignant Pleural Mesothelioma ◽  
High Dose ◽  
Pleural Mesothelioma ◽  
Long Term Follow Up

scholarly journals P3.03-031 Definitive Radiation Therapy is Associated with Improved Survival in Non-Metastatic Malignant Pleural Mesothelioma

2017 ◽  
Vol 12 (1) ◽  
pp. S1363-S1364
Author(s):  
Kenneth Rosenzweig ◽  
Nisha Ohri ◽  
Andrea Wolf ◽  
Jorge Gomez ◽  
Raja Flores ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

scholarly journals Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs

2019 ◽  
Vol 9 (3) ◽  
pp. e331-e337 ◽  
Author(s):  
Marcher R. Thompson ◽  
Vishruta A. Dumane ◽  
Stanislav A. Lazarev ◽  
Yaseen Zia ◽  
Kenneth E. Rosenzweig
Keyword(s):  
Radiation Therapy ◽  
Malignant Pleural Mesothelioma ◽  
Pulmonary Toxicity ◽  
Pleural Mesothelioma

scholarly journals Immunotherapy and radiation therapy for malignant pleural mesothelioma

2007 ◽  
Vol 6 (2) ◽  
pp. 212-219 ◽  
Author(s):  
Evan W. Alley ◽  
Sharyn I. Katz ◽  
Keith A. Cengel ◽  
Charles B. Simone II
Keyword(s):  
Radiation Therapy ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Therapeutic targeting of polyamines in malignant pleural mesothelioma xenograft models.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20060-e20060
Author(s):  
James C. M. Ho ◽  
Sheng Yan ◽  
Sze Kwan Lam
Keyword(s):  
Adjuvant Therapy ◽  
Tumor Growth ◽  
Malignant Pleural Mesothelioma ◽  
Nude Mice ◽  
Pleural Mesothelioma ◽  
Term Survival ◽  
Early Stage Disease ◽  
Therapeutic Setting ◽  
Metastatic Setting ◽  
Humane Endpoint

e20060 Background: Although the use of asbestos has been restricted, the incidence of malignant pleural mesothelioma (MPM) is still rising. The US FDA approved a combination of pemetrexed with cisplatin for treatment of unresectable MPM. And development of novel adjuvant therapeutic options for resected early-stage disease is also urgently needed. From our preliminary data, ornithine decarboxylase (ODC) is highly expressed in MPM xenografts and clinical tumor samples. Upregulation of ODC increases polyamines production and enhances tumor growth. a-difluoromethylornithine (DFMO) is a specific ODC inhibitor. This study aims to disclose the adjuvant (minimal residual disease setting) and therapeutic (metastatic setting) effects of DFMO in MPM xenografts. Methods: In adjuvant therapy setting, nude mice were fed with DFMO in drinking water 7 days before subcutaneous inoculation of 200,000 tumor cells. In therapeutic setting, 107 corresponding cells were injected subcutaneously into nude mice which were randomized for treatment after established tumor growth. Mice with tumor size > 600mm3 were considered reaching humane endpoint. Spermidine levels, protein expression, cytokines concentration, and apoptosis were investigated by Dot plot, Western blot, ELISA, and TUNEL assay respectively. Results: In adjuvant therapy setting, DFMO suppressed tumor growth and increased median survival in both 211H and H226 xenografts. In H226 xenografts, 43% of treated mice have not yet reached humane endpoint, mimicking long-term survival. Upon DFMO treatment, decrease in spermidine level, increase in nitrotyrosine content, and activation of apoptosis were observed in both xenografts. In addition, increase in nitrosocysteine level, intratumoral IL-6, keratinocyte chemoattractant and TNFα, DNA lesions and inhibition of Akt/mTOR pathway were induced by DFMO in H226 xenografts, which may explain higher potency of DFMO in these xenografts. In therapeutic setting, DFMO also suppressed tumor growth in both xenografts with similar mechanisms. Conclusions: DFMO may have a potential role as adjuvant therapy in MPM especially epithelioid mesothelioma.

Sign in / Sign up

Export Citation Format

Share Document